Gurudatta Naik

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Burden of Central Nervous System Cancer in the United States, 1990-2021

  JAMA Neurology · 2025-11-03 · 1 citations

• Robotic repair of off-midline abdominal wall hernias: a single institution consecutive case series

  Hernia · 2025-09-29 · 1 citations

• RETROSPECTIVE STUDY ON CORRELATION OF MAGNETIC RESONANCE SPECTROSCOPY WITH HISTOPATHOLOGICAL EXAMINATION IN SUPRATENTORIAL BRAIN TUMORS

  INTERNATIONAL JOURNAL OF SCIENTIFIC RESEARCH · 2025-08-01

• Retrospective Study on Correlation of Magnetic Resonance Spectroscopy with Histopathological Examination in Supratentorial Brain Tumors

  International Journal of Science and Research (IJSR) · 2025-07-23

• Patients’ perceptions of bariatric surgery in the Deep South: the impact of health literacy

  Surgical Endoscopy · 2025-07-08 · 1 citations

• Mo1820: READINESS FOR CHANGE AMONG PROVIDERS IN IMPLEMENTATION OF ENHANCED RECOVERY PROGRAMS

  Gastroenterology · 2025-05-01

• 450: PATIENTS’ PERSPECTIVES OF BARIATRIC SURGICAL CARE IN THE DEEP SOUTH: A QUALITATIVE STUDY

  Gastroenterology · 2025-05-01

• Table S3 from Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>Preprint

  2024-10-29

• Protocol Link from Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>Preprint

  2024-10-29

• Table S1 from Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>Preprint

  2024-10-29

• Data from Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>Preprint

  2024-10-29

• Figure S1 from Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>Preprint

  2024-10-29

• Table S4 from Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>Preprint

  2024-10-29

• Table S2 from Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>Preprint

  2024-10-29

• Experimental Methods for MDMX Gene Expression Analysis from Patient Tumor Specimens from Phase 1 Trial of ALRN-6924, a Dual Inhibitor of MDMX and MDM2, in Patients with Solid Tumors and Lymphomas Bearing Wild-type <i>TP53</i>Preprint

  2024-10-29

• Early postoperative outcomes following bariatric surgery in the United States: Are racial disparities improving?

  Surgical Endoscopy · 2024-07-26 · 3 citations